47622_S105
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.360
- TGF_BETA_SIGNALING+0.360
- ANDROGEN_RESPONSE+0.280
- INTERFERON_ALPHA_RESPONSE+0.260
- INTERFERON_GAMMA_RESPONSE+0.260
- UV_RESPONSE_DN+0.220
- ALLOGRAFT_REJECTION+0.140
- TNFA_SIGNALING_VIA_NFKB+0.130
- FATTY_ACID_METABOLISM+0.120
- COMPLEMENT+0.110
Top 10 suppressed
- MYC_TARGETS_V2-0.430
- WNT_BETA_CATENIN_SIGNALING-0.380
- E2F_TARGETS-0.330
- G2M_CHECKPOINT-0.290
- NOTCH_SIGNALING-0.240
- PANCREAS_BETA_CELLS-0.210
- ANGIOGENESIS-0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.180
- MITOTIC_SPINDLE-0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | dcabd821.c5d5.4a97.b657.0612d6a4439d | — | cohortA1 | 0.780 |
| 2 | C3L-02348 | — | cohortA1 | 0.771 |
| 3 | 7c025d06-2593-493c-b4a5-9f976149b0e2 | — | — | 0.743 |
| 4 | ULC0422T_S31 | — | cohortA1 | 0.711 |
| 5 | R342 | — | — | 0.710 |
| 6 | C3L-02549 | — | cohortA1 | 0.704 |
| 7 | MNG627 | — | — | 0.702 |
| 8 | SRR12475115 | — | — | 0.701 |
| 9 | TCGA-E2-A1L8-01A-11R-A13Q-07 | — | B | 0.701 |
| 10 | SRR12475112 | — | — | 0.701 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |